IOVA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IOVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
Iovance Biotherapeutics's adjusted revenue per share for the three months ended in Mar. 2024 was $0.003. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.01 for the trailing ten years ended in Mar. 2024.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.
As of today (2024-05-14), Iovance Biotherapeutics's current stock price is $10.72. Iovance Biotherapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.01. Iovance Biotherapeutics's Cyclically Adjusted PS Ratio of today is 1,072.00.
During the past 13 years, the highest Cyclically Adjusted PS Ratio of Iovance Biotherapeutics was 1679.00. The lowest was 333.00. And the median was 784.00.
The historical data trend for Iovance Biotherapeutics's Cyclically Adjusted Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iovance Biotherapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted Revenue per Share | Get a 7-Day Free Trial | - | - | 0.01 | 0.01 | 0.01 |
For the Biotechnology subindustry, Iovance Biotherapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's Cyclically Adjusted PS Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?
Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.
We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Iovance Biotherapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0.003 | / | 129.4194 | * | 129.4194 | |
= | 0.003 |
Current CPI (Mar. 2024) = 129.4194.
Iovance Biotherapeutics Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.000 | 100.560 | 0.000 |
201409 | 0.000 | 100.428 | 0.000 |
201412 | 0.000 | 99.070 | 0.000 |
201503 | 0.000 | 99.621 | 0.000 |
201506 | 0.000 | 100.684 | 0.000 |
201509 | 0.000 | 100.392 | 0.000 |
201512 | 0.000 | 99.792 | 0.000 |
201603 | 0.000 | 100.470 | 0.000 |
201606 | 0.000 | 101.688 | 0.000 |
201609 | 0.000 | 101.861 | 0.000 |
201612 | 0.000 | 101.863 | 0.000 |
201703 | 0.000 | 102.862 | 0.000 |
201706 | 0.000 | 103.349 | 0.000 |
201709 | 0.000 | 104.136 | 0.000 |
201712 | 0.000 | 104.011 | 0.000 |
201803 | 0.000 | 105.290 | 0.000 |
201806 | 0.000 | 106.317 | 0.000 |
201809 | 0.000 | 106.507 | 0.000 |
201812 | 0.000 | 105.998 | 0.000 |
201903 | 0.000 | 107.251 | 0.000 |
201906 | 0.000 | 108.070 | 0.000 |
201909 | 0.000 | 108.329 | 0.000 |
201912 | 0.000 | 108.420 | 0.000 |
202003 | 0.000 | 108.902 | 0.000 |
202006 | 0.000 | 108.767 | 0.000 |
202009 | 0.000 | 109.815 | 0.000 |
202012 | 0.000 | 109.897 | 0.000 |
202103 | 0.000 | 111.754 | 0.000 |
202106 | 0.000 | 114.631 | 0.000 |
202109 | 0.000 | 115.734 | 0.000 |
202112 | 0.000 | 117.630 | 0.000 |
202203 | 0.000 | 121.301 | 0.000 |
202206 | 0.000 | 125.017 | 0.000 |
202209 | 0.000 | 125.227 | 0.000 |
202212 | 0.000 | 125.222 | 0.000 |
202303 | 0.000 | 127.348 | 0.000 |
202306 | 0.001 | 128.729 | 0.001 |
202309 | 0.002 | 129.860 | 0.002 |
202312 | 0.002 | 129.419 | 0.002 |
202403 | 0.003 | 129.419 | 0.003 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.
For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Iovance Biotherapeutics's Cyclically Adjusted PS Ratio of today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 10.72 | / | 0.01 | |
= | 1,072.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
During the past 13 years, the highest Cyclically Adjusted PS Ratio of Iovance Biotherapeutics was 1679.00. The lowest was 333.00. And the median was 784.00.
Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.
Thank you for viewing the detailed overview of Iovance Biotherapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Merrill A Mcpeak | director | PO BOX 500 (M/S 55-985), 14200 SW KARL BRAUN DRIVE, BEAVERTON OR 97077-0001 |
Wayne P. Rothbaum | director | C/O QUOGUE CAPITAL LLC, 1285 AVENUE OF THE AMERICAS, 35TH FLOOR, NEW YORK NY 10019 |
Wendy L Yarno | director | |
Frederick G Vogt | officer: General Counsel | 2120 HEMLOCK RD., WEST NORRITON PA 19403 |
Iain D. Dukes | director | 112 W. 34TH STREET, 17TH FLOOR, NEW YORK NY 10120 |
Wendy L Dixon | director | |
Ryan D Maynard | director | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Michael Weiser | director | C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133 |
Igor Bilinsky | officer: Chief Operating Officer | C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121 |
Jean-marc Bellemin | officer: Chief Financial Officer | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Michael Swartzburg | officer: VP, Finance | C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025 |
Athena Countouriotis | director | C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
Finckenstein Friedrich Graf | officer: Chief Medical Officer | 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070 |
Timothy E Morris | officer: Chief Financial Officer | ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
Maria Fardis | director, officer: President and CEO | C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
From GuruFocus
By GlobeNewswire • 12-22-2023
By Marketwired • 07-10-2023
By PRNewswire • 12-28-2023
By Marketwired • 09-27-2023
By GuruFocus Research • 12-27-2023
By GlobeNewswire • 08-18-2023
By Marketwired • 08-08-2023
By sperokesalga sperokesalga • 06-15-2023
By Marketwired • 10-16-2023
By GlobeNewswire • 01-19-2024